Aidan Finley

@afinley

Biotech nerd. Tweets are my own.

Cambridge, MA
Vrijeme pridruživanja: travanj 2007.

Tweetovi

Blokirali ste korisnika/cu @afinley

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @afinley

  1. prije 4 sata

    Beautiful (a muddy field transformed by human ingenuity into a hospital!)

    Poništi
  2. proslijedio/la je Tweet
    20. sij

    A brief history of AMG 510 and friends. How fragment-based insights brought multiple drug candidates to the clinic against the formerly undruggable target KRAS.

    Poništi
  3. proslijedio/la je Tweet
    1. sij
    Poništi
  4. proslijedio/la je Tweet
    28. pro 2019.

    2019 SM Drug Approvals w/ Indication, Mechanism, and Dosing - - ChemDraw file available for download for our little community of drug hunters. Looking forward to 2020!

    Poništi
  5. proslijedio/la je Tweet

    Learn valuation & corporate finance this spring from Aswath Damodaran of NYU. For free!

    Poništi
  6. proslijedio/la je Tweet

    The way in which openly looks down on people who didn’t go to college does not just represent a personal failing on her part, it taps into a growing trend that is damaging American society. I’ve been writing about this for almost a decade.

    Prikaži ovu nit
    Poništi
  7. proslijedio/la je Tweet

    For the first time ever, the hedcut tradition is available to all of our members. Come on over, and get your own... Here's mine:

    Poništi
  8. proslijedio/la je Tweet
    14. pro 2019.

    Outstanding, comprehensive overview of the biology and management of lymphoma in 2019. Well worth checking out!

    Poništi
  9. proslijedio/la je Tweet
    Odgovor korisniku/ci

    It's ironic that the two most potentially destructive politicians to our industry represent the two biggest biotech clusters SF and Massachusetts.

    Poništi
  10. proslijedio/la je Tweet
    29. stu 2019.

    Our newest paper just came out in Nature Genetics! "Histone hyperacetylation disrupts core gene regulatory architecture in rhabdomyosarcoma"

    Prikaži ovu nit
    Poništi
  11. 15. stu 2019.

    Welcome Adakveo! ($NVS, Selexys)

    Poništi
  12. proslijedio/la je Tweet
    7. stu 2019.

    V interesting: PFS has mushroomed as a primary endpoint in trials but this may not be appropriate or helpful. 2 reasons for treating a pt with cancer: - prolong life - improve QoL PFS doesn't necessarily predict either. Thanks to for ref

    Poništi
  13. proslijedio/la je Tweet

    My take on $AZN’s thing: It’s important not b/c of what it says about China as a future market for pharma. Astra already checked that box long ago. The real significance is this is Astra signaling how China will be a future source of innovation for our industry. That’s the news.

    Poništi
  14. proslijedio/la je Tweet
    21. lis 2019.

    1989, gene and most common F508del mutation identified by & co. 2019, FDA approves Trikafta for pts with at least one F508del An incredible 30-yr journal from gene discovery to personalized medicine that highlights the impact of innovation!

    Poništi
  15. proslijedio/la je Tweet
    7. lis 2019.

    On the occasion of his extremely well deserved Nobel Prize for co-discovery of oxygen sensing pathways, I recommend that everyone read his Nature commentary: Publish Houses of Brick, Not Mansions of Straw. Right on target.

    Poništi
  16. proslijedio/la je Tweet

    I laughed, I cried from laughing, I laughed some more

    Poništi
  17. proslijedio/la je Tweet
    5. lis 2019.

    Nice diagram although I would argue rituximab was the start of immune therapies.

    Poništi
  18. proslijedio/la je Tweet
    5. lis 2019.

    "The Education of an Idealist" is a curious title for a tale almost entirely bereft of idealism, as is the case with a new memoir by , which I've gently examined in :

    Poništi
  19. proslijedio/la je Tweet
    4. lis 2019.

    The really amazing thing, to me, about this result is how close it is to my previous estimate of 2.9B using equity (2.3B using options), despite using completely different inputs in a completely new model!

    Tweet je nedostupan.
    Poništi
  20. proslijedio/la je Tweet
    28. ruj 2019.

    Just 10 yrs ago, only 1 in 20 patients with advanced would survive for five yrs Now, more than half of pts survive for at least 5yrs with nivo+ipi combo This is cancer "long tail" at its best!

    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·